Carolinas HealthCare System
View Our Locations
Practice Map

Services for Multiple Sclerosis at CMC Neurology

Carolinas Multiple Sclerosis Center offers state-of-the-art resources to provide the advanced specialized care, research and education. Recognized as a leader in the research and treatment of multiple sclerosis, Carolinas MS Center provides patients with individualized treatment plans formulated to help them sustain greater functionality over the course of their illness.

Our center offers a comprehensive, team-oriented approach to patient care that includes physicians, physical therapists, occupational therapists, speech therapists, a social worker, counseling for depression/anxiety and a dietitian.

Address the Needs of Each MS Patient

Our comprehensive program is equipped to handle the wide range of symptoms that normally makes the disease difficult to treat. Michael Kaufman, MD and Jill Conway, MD along with their dedicated team, focus on addressing the physical, emotional, cognitive and rehabilitation needs of each MS patient and their family members. Our specialists assist patients from diagnosis to disease management to physical therapy, while participating in research studies that offer the most innovative therapies.

Dr. Kaufman was recently named as President-Elect of the Consortium of MS Centers, the largest organization of MS providers with worldwide membership of more than 130 centers. He was also recently appointed Chairman of the Integration Panel of the Department of Defense Congressionally Directed MS Research Program.

Carolinas MS Center provides significant clinical research opportunities available for patients, ranging from genetic studies to trials of new treatments. Our specialists are nationally recognized for their contributions to MS research - conducting more than 60 research trials since 1993.

For more information about our multiple sclerosis services, please call 704-446-1900.

Clinical trials available for multiple sclerosis patients

ASCEND: Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis Biogen Idec The main purpose of this research study is to see if natalizumab is effective in slowing the progression of disability independently of relapse in SPMS. Jacqueline Foster
704-446-1909
MASITINIB: Study to compare efficacy and safety of masitinib versus placebo on the treatment of patients with primary progressive or relapse-free secondary progressive multiple sclerosis AB Science This study is being conducted to determine if the experimental drug, Masitinib, is safe and effective in patients with Primary Progressive or relapse-free Secondary Progressive Multiple Sclerosis.

View Consent Form

Natasha Swayne
704-446-1987
COGNITION & MENTAL FATIGUE:  Computerized cognitive testing scores sensitized by mental fatigue Biogen Idec The purpose of this study to find an effective way of predicting which patients will suffer a faster decline in their ability to think, concentrate, understand instructions, reason and accomplish minor tasks.

View Consent Form

Leonora Kaufmann
704-446-0803
The M.U.R.D.O.C.K. Study Registry and Biorepository Duke The purpose of this project is to collect and store blood and urine samples and health information in order to find new ways to detect, treat, and possibly prevent or cure health problems.

View Consent Form

Rita Rouse
704-446-1902
ORATORIO: Study to evaluate the efficacy and safety of ocrelizumab in adults with Primary Progressive MS Hoffmann/
LaRoche
This study is being conducted to determine whether the drug ocrelizumab is safe and effective as a treatment for Primary Progressive Multiple Sclerosis.

Visit ClinicalTrials.gov

Jacqueline Foster
704-446-1909
OPERA: Study to Evaluate the Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif®) In Patients With Relapsing Multiple Sclerosis Hoffmann/
LaRoche
This study is being conducted to confirm whether patients treated with ocrelizumab may experience even fewer clinical relapses than those treated with Rebif.

Visit ClinicalTrials.gov

Cynthia Lary
704-446-6063
STRATIFY-2: JCV Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Tysabri Biogen Idec The purpose of this study is to better understand whether antibodies to the JC Virus may be used to predict whether a patient using Tysabri is at higher or lower risk for developing Progressive Multifocal Leukoencephalopathy (PML).

Visit ClinicalTrials.gov

View Consent Form

Rita Rouse
704-446-1902
DECIDE: Study to Determine the Efficacy and Safety of Daclizumab High Yield Process versus Avonex® (Interferon β-1a) in Patients with Relapsing-Remitting Multiple Sclerosis Biogen Idec This study is being conducted to determine whether DAC HYP, a type of antibody made in the laboratory, is superior to Avonex at preventing relapses in patients with RRMS.

Visit ClinicalTrials.gov

View Consent Form

Joyce Pitner
704-446-1349
About Carolinas HealthCare System
Who We Are
Leadership
Community Benefit
Corporate Financial Information
Diversity & Inclusion
Annual Report
Foundation
Patient Links
Pay Your Bill
Hospital Pre-Registration
Patient Rights
Privacy Policy
Financial Assistance
Quality & Value Reports
Insurance
Careers
Join Carolinas HealthCare System
Physician Careers

For Employees
Carolinas Connect
Connect with Us
Watch Carolinas HealthCare on YoutubeFollow Carolinas HealthCare on TwitterLike Carolinas HealthCare on FacebookContact Carolinas HealthCareJoin Carolinas HealthCare on LinkedInGo to our mobile website.